Beam Therapeutics BEAM 深 沪
等待开盘 05-14 09:30:00 美东时间
31.85
+0.270
+0.85%
华盛通- 最 高32.53
- 今 开31.00
- 成交量 282.35万股
- 最 低 31.00
- 昨 收 31.58
- 总市值 32.72亿
- 52周最高 36.44
- 市盈率 静 --
- 换手率 2.75%
- 52周最低 15.35
- 委 比 81.33%
- 总股本 1.03亿
- 历史最高 138.522
- 量 比 1.33
- 振 幅 4.84%
- 历史最低 13.00
- 每 手 1
- 风险率 4.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bernstein Maintains Outperform on Beam Therapeutics, Lowers Price Target to $39
Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $40 to $39.
今天 02:34
财报速睇 | Beam Therapeutics 2026财年Q1营收0.32亿美元，同比增长357.1%；归母净利润亏损0.94亿美元，同比亏损缩窄13.0%
华盛资讯5月7日讯，Beam Therapeutics公布2026财年Q1业绩，公司Q1营收0.32亿美元，同比增长357.1%，归母净利润亏损0.94亿美元，同比亏损缩窄13.0%。
05-07 20:30
财报速睇 | Beam Therapeutics 2026财年Q1营收0.32亿美元，同比增长357.1%；归母净利润亏损0.94亿美元，同比亏损缩窄13.0%
华盛资讯5月7日讯，Beam Therapeutics公布2026财年Q1业绩，公司Q1营收0.32亿美元，同比增长357.1%，归母净利润亏损0.94亿美元，同比亏损缩窄13.0%。
05-07 19:32
Beam Therapeutics Q1 EPS $(0.91) Beats $(1.09) Estimate, Sales $31.738M Beat $10.977M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.09) by 16.51 percent. This is a 26.02 percent increase over losses of $(1.23) per share from
05-07 19:24
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Beam Therapeutics reported strong progress in Q1 2026, including positive clinical data for BEAM-302 in AATD, with 60 mg selected as the optimal dose, and plans to initiate a pivotal cohort later this year. The BEACON trial data for risto-cel in sickle cell disease were published in the New England Journal of Medicine, with a BLA submission expected by year-end 2026. The company also anticipates IND filings for BEAM-304 in PKU and expects to repo...
05-07 11:00
XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY, JBIO, BEAM.
04-27 22:20
Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM
Cathie Wood’s ARK Invest funds have delivered mixed performance in the recent period, with ARK Space & Defense Innovation ETF (ARKX) up 1.27% and ARK Autonomous Technology & Robotics ETF (ARKQ) margin...
04-04 02:25
Beam Therapeutics Publishes BEACON Phase 1/2 Data For Risto-Cel In Patients With Sickle Cell Disease In The New England Journal of Medicine; U.S. Biologics License Application Submission for Risto-Cel Expected As Early As Year-End 2026
Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)Initially Presented at ASH, Data from 31 Patients with SCD
04-02 05:17
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Beam Therapeutics announced the publication of interim data from the Phase 1/2 BEACON trial in *The New England Journal of Medicine*, demonstrating ristoglogene autogetemcel (risto-cel)'s potential to significantly improve outcomes for patients with sickle cell disease (SCD) and severe vaso-occlusive crises (VOCs). Data from 31 patients showed rapid engraftment, hemoglobin improvements mimicking sickle cell trait, and no severe VOCs post-treatmen...
04-01 21:12
Beam Therapeutics发布BEAM-302临床数据加速AATD治疗赛道分化
声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。 29例患者随...
03-29 10:31
